Dr Reddys Laboratories (RDY) Assets Average (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Assets Average of $6.0 billion for Q1 2026, up 14.63% year-on-year from $5.2 billion in Q1 2025, and up 14.63% on a QoQ basis from $5.2 billion in Q1 2025.
Dr Reddys Laboratories (RDY) Assets Average (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Assets Average for 3 consecutive years, with $6.0 billion the latest figure, recorded in Q1 2026.
- Quarterly Assets Average rose 14.63% year-over-year to $6.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 billion (up 14.63% YoY) and the FY2026 annual result came in at $6.0 billion, up 14.63% from the prior year.
- Assets Average climbed to $6.0 billion in Q1 2026 per RDY's latest filing, from $5.2 billion in the prior quarter.
- Over the last five years, Assets Average for RDY reached as high as $6.0 billion in Q1 2026 and fell as low as $5.2 billion in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | 5.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.97 Bn |
| Mar 31, 2025 | 5.21 Bn |
| Dec 31, 2009 | 1.64 Bn |
| Sep 30, 2009 | 1.74 Bn |